Matches in Wikidata for { <http://www.wikidata.org/entity/Q61613759> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q61613759 description "artículu científicu espublizáu en xunu de 2006" @default.
- Q61613759 description "im Juni 2006 veröffentlichter wissenschaftlicher Artikel" @default.
- Q61613759 description "scientific article published on 01 June 2006" @default.
- Q61613759 description "wetenschappelijk artikel" @default.
- Q61613759 description "наукова стаття, опублікована в червні 2006" @default.
- Q61613759 name "Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome" @default.
- Q61613759 name "Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome" @default.
- Q61613759 type Item @default.
- Q61613759 label "Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome" @default.
- Q61613759 label "Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome" @default.
- Q61613759 prefLabel "Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome" @default.
- Q61613759 prefLabel "Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome" @default.
- Q61613759 P1433 Q61613759-BA814439-E93B-4197-801E-6D80BCD50CE2 @default.
- Q61613759 P1476 Q61613759-1A16330E-1096-4FED-9572-B350AB2C9257 @default.
- Q61613759 P2093 Q61613759-1B1F6D7F-9D84-4DC9-85F4-23D8F307E25B @default.
- Q61613759 P2093 Q61613759-601FAE87-17A9-47C1-92B8-E164295881C9 @default.
- Q61613759 P2093 Q61613759-6403A203-5F1D-47E0-BB67-162B7099E445 @default.
- Q61613759 P2093 Q61613759-B81E1D91-8448-4CCD-B93E-EE9493EDE3C3 @default.
- Q61613759 P2093 Q61613759-FD56A3CF-46CA-428B-807E-3A0FD6CF75E2 @default.
- Q61613759 P304 Q61613759-1CBEE4F2-73A8-4C32-BE05-9C03D4921BF7 @default.
- Q61613759 P31 Q61613759-DDE49195-8584-407E-BC74-388CE7F67C71 @default.
- Q61613759 P356 Q61613759-BAD5FDCE-FEE1-41F9-A9F2-C59F4F072B89 @default.
- Q61613759 P433 Q61613759-7EC8B968-7FC9-40D5-B3F8-F3BB77098E56 @default.
- Q61613759 P478 Q61613759-48EDB836-1DCF-49FA-936F-1772BFB1C6D2 @default.
- Q61613759 P50 Q61613759-92D702D2-D26F-449E-A85B-81FD92CF2DE5 @default.
- Q61613759 P50 Q61613759-C6520111-2103-429E-9E82-E4FECF8D5CC4 @default.
- Q61613759 P577 Q61613759-53A7749A-0AC6-498B-8864-98F549425D7A @default.
- Q61613759 P698 Q61613759-6A2D7523-3886-4392-A0C5-D8A69E14164C @default.
- Q61613759 P356 J.1442-2042.2006.01387.X @default.
- Q61613759 P698 16834644 @default.
- Q61613759 P1433 Q15767019 @default.
- Q61613759 P1476 "Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome" @default.
- Q61613759 P2093 "1032 Study Group" @default.
- Q61613759 P2093 "Dzelal Serdarevic" @default.
- Q61613759 P2093 "Katherine Hargreaves" @default.
- Q61613759 P2093 "Paul Abrams" @default.
- Q61613759 P2093 "Vikram Khullar" @default.
- Q61613759 P304 "692-698" @default.
- Q61613759 P31 Q13442814 @default.
- Q61613759 P356 "10.1111/J.1442-2042.2006.01387.X" @default.
- Q61613759 P433 "6" @default.
- Q61613759 P478 "13" @default.
- Q61613759 P50 Q37831462 @default.
- Q61613759 P50 Q4793466 @default.
- Q61613759 P577 "2006-06-01T00:00:00Z" @default.
- Q61613759 P698 "16834644" @default.